GSK plc (NYSE:GSK) Shares Purchased by AdvisorNet Financial Inc

AdvisorNet Financial Inc boosted its holdings in GSK plc (NYSE:GSKGet Rating) by 5.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,436 shares of the pharmaceutical company’s stock after purchasing an additional 1,324 shares during the quarter. AdvisorNet Financial Inc’s holdings in GSK were worth $1,107,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the business. KG&L Capital Management LLC increased its stake in GSK by 0.8% in the first quarter. KG&L Capital Management LLC now owns 29,611 shares of the pharmaceutical company’s stock valued at $1,290,000 after purchasing an additional 225 shares during the last quarter. Koss Olinger Consulting LLC increased its stake in GSK by 3.4% in the first quarter. Koss Olinger Consulting LLC now owns 7,299 shares of the pharmaceutical company’s stock valued at $318,000 after purchasing an additional 242 shares during the last quarter. Steel Peak Wealth Management LLC increased its stake in GSK by 4.6% in the first quarter. Steel Peak Wealth Management LLC now owns 5,543 shares of the pharmaceutical company’s stock valued at $241,000 after purchasing an additional 246 shares during the last quarter. Tsfg LLC increased its stake in GSK by 67.9% in the first quarter. Tsfg LLC now owns 618 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 250 shares during the last quarter. Finally, Glassman Wealth Services grew its position in GSK by 71.3% during the fourth quarter. Glassman Wealth Services now owns 627 shares of the pharmaceutical company’s stock valued at $28,000 after acquiring an additional 261 shares during the period. 16.86% of the stock is currently owned by institutional investors and hedge funds.

GSK Price Performance

Shares of NYSE GSK opened at $30.83 on Friday. GSK plc has a 1-year low of $30.49 and a 1-year high of $46.97. The business has a 50-day moving average of $36.90 and a 200-day moving average of $41.24. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.43 and a quick ratio of 1.31. The company has a market capitalization of $62.70 billion, a price-to-earnings ratio of 10.21, a PEG ratio of 1.18 and a beta of 0.61.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 6th. Investors of record on Friday, August 19th will be paid a $0.383 dividend. This is a boost from GSK’s previous quarterly dividend of $0.35. The ex-dividend date is Thursday, August 18th. This represents a $1.53 annualized dividend and a dividend yield of 4.97%. GSK’s payout ratio is 50.66%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on GSK. UBS Group lowered their price target on GSK from GBX 1,876 ($22.67) to GBX 1,850 ($22.35) in a research report on Wednesday, July 20th. TheStreet downgraded GSK from a “b” rating to a “c+” rating in a research report on Monday, August 29th. AlphaValue downgraded GSK to a “reduce” rating in a research report on Tuesday, July 19th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating in a research report on Thursday, September 8th. Finally, Morgan Stanley lowered their price target on GSK from GBX 1,860 ($22.47) to GBX 1,550 ($18.73) in a research report on Wednesday, September 7th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $1,700.00.

GSK Profile

(Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Articles

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKGet Rating).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.